EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

EpiCast Report: Alzheimers Disease - Epidemiology Forecast to 2026

Summary

Alzheimers disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities such as thinking, language, and learning capacity. Mild cognitive impairment (MCI) is a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory loss and thinking skills, but no dementia. MCI presents as an intermediate stage between the cognitive decline that occurs with normal aging and the onset of dementia.

To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM, GlobalData epidemiologists utilized country-specific population-based studies. GlobalData epidemiologists further categorized the AD total prevalent cases based on severity as mild, moderate, and severe. Similarly, GlobalData epidemiologists selected country-specific studies with a consistent definition of MCI to forecast the total prevalent cases of MCI in the 7MM. GlobalData epidemiologists kept the forecast methodology consistent across the 7MM in order to allow for a meaningful comparison of the forecast total prevalent cases across the markets.

In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of AD from 10,604,756 total prevalent cases in 2016 to 13,759,918 total prevalent cases in 2026, at an annual growth rate (AGR) of 2.98% during the forecast period. Among the 7MM, the US will have the highest number of total prevalent cases of AD throughout the forecast period, while the UK will have the lowest.

Scope

- The Alzheimers Disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age (ages 60 years and older) in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Alzheimers Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
- Understand severity of prevalent AD cases and total prevalent cases of MCI.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.4 Forecast Methodology 11
3.4.1 Sources 11
3.4.2 Forecast Assumptions and Methods 14
3.4.3 Total Prevalent Cases of AD 14
3.4.4 Total Prevalent Cases of AD by Severity 17
3.4.5 Total Prevalent Cases of MCI 20
3.5 Epidemiological Forecast for AD (2016-2026) 22
3.5.1 Total Prevalent Cases of AD 22
3.5.2 Age-Specific Total Prevalent Cases of AD 23
3.5.3 Sex-Specific Total Prevalent Cases of AD 24
3.5.4 Total Prevalent Cases of AD by Severity 25
3.6 Epidemiological Forecast for MCI (2016-2026) 26
3.6.1 Total Prevalent Cases of MCI 26
3.6.2 Age-Specific Total Prevalent Cases of MCI 27
3.6.3 Sex-Specific Total Prevalent Cases of MCI 28
3.7 Discussion 29
3.7.1 Epidemiological Forecast Insight 29
3.7.2 Limitations of Analysis 29
3.7.3 Strengths of Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 35
4.2.1 Epidemiologist 35
4.2.2 Reviewers 35
4.2.3 Global Director of Therapy Analysis and Epidemiology 36
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
4.3 About GlobalData 37
4.4 Contact Us 37
4.5 Disclaimer 37

List Of Tables

Table 1: DSM-IV Criteria for the Diagnosis of Dementia 8
Table 2: NINCDS-ADRDA Criteria for the Diagnosis of AD 8
Table 3: Risk Factors and Comorbidities for AD 9
Table 4: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages 60 Years, Selected Years 2016-2026. 22
Table 5: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages 60 Years, Selected Years 2016-2026. 26

List Of Figures

Figure 1: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages 60 Years, 2016 and 2026 5
Figure 2: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages 60 Years , 2016 and 2026 5
Figure 3: 7MM, Age-Standardized Total Prevalence of AD (%), Ages 60 Years 10
Figure 4: 7MM, Age-Standardized Total Prevalence of MCI (%), Ages 60 Years 11
Figure 5: 7MM, Sources Used and Not Used, Total Prevalent Cases of AD 12
Figure 6: 7MM, Sources Used, Total Prevalent Cases of AD by Severity 13
Figure 7: 7MM, Sources Used, Total Prevalent Cases of MCI 14
Figure 8: 7MM, Age-Specific Total Prevalent Cases of AD, Both Sexes, 2016 23
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of AD, Both Sexes, Ages >60 Years, 2016 24
Figure 10: 7MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages 60 Years, 2016 25
Figure 11: 7MM, Age-Specific Total Prevalent Cases of MCI, Both Sexes, 2016 27
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of MCI, Both Sexes, Ages >60 Years, 2016 28

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available